Changchun Genescience Pharmaceutical Co., Ltd.
Clinical trials sponsored by Changchun Genescience Pharmaceutical Co., Ltd., explained in plain language.
-
First human test for new Graves' disease drug begins
Disease control Recruiting nowThis early-stage study is testing the safety of a new medication called GenSci098 for people with Graves' disease, an autoimmune condition that causes overactive thyroid. Researchers will give 24 participants increasing doses of the drug to check for side effects and see how the …
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 22:41 UTC
-
New growth shot tested to help short kids catch up
Disease control Recruiting nowThis study is testing whether a new, longer-acting growth hormone injection works better than the standard version for children who are short because they were born small for their gestational age. About 72 prepubertal children will receive either one of two doses of the new medi…
Phase: PHASE2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
First patients to test new cancer drug in global trial
Disease control Recruiting nowThis is the first time a new drug called GenSci139 is being tested in people. The study aims to find a safe dose and see how the body processes the drug in patients with advanced solid tumors that have spread or cannot be removed by surgery. Researchers will also look for early s…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New eye disease drug enters human testing phase
Disease control Recruiting nowThis early-stage study aims to test the safety and side effects of a new injectable drug called GenSci098 in people with thyroid eye disease. Researchers will give increasing doses to 76 participants to see how their bodies handle the medication and monitor for any problems. The …
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
First patients to test new hope for Tough-to-Treat cancers
Disease control Recruiting nowThis is the first study in people to test a new drug called GenSci143 for advanced solid tumors. The main goals are to find a safe dose and see how the body processes the drug. It is for adults whose cancer has continued to grow despite standard treatments or who have no other tr…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for tough cancers: first patients test experimental drug
Disease control Recruiting nowThis is the first study in people to test a new drug called GenSci140 for advanced solid tumors, like ovarian cancer. The main goals are to find a safe dose, understand how the body processes the drug, and see if it shows any early signs of helping to control the cancer. The stud…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for women with hormone disorder: which drug works better?
Disease control Recruiting nowThis study aims to find out which of two existing medications works better for women with high prolactin levels, a hormone condition that can affect menstrual cycles and fertility. Researchers will compare cabergoline tablets against bromocriptine tablets in 382 female participan…
Phase: PHASE3 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
First-in-Human trial launches for new targeted cancer pill
Disease control Recruiting nowThis is the first study in people to test a new oral drug called GenSci128. It aims to see if the drug is safe and tolerable for patients with advanced solid tumors that have a specific genetic mutation called TP53 Y220C. The study will also look at how the drug moves through the…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 03, 2026 14:06 UTC
-
New hope for fighting cancer wasting? Real-World study tests appetite drug
Symptom relief Recruiting nowThis study is observing how well an existing medication works for cancer patients suffering from cachexia, a condition causing severe weight loss and loss of appetite. It will follow 495 adult patients who are already scheduled to take the drug in their normal care. The main goal…
Phase: PHASE4 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Apr 01, 2026 22:40 UTC
-
New hope to fight wasting in lung cancer patients
Symptom relief Recruiting nowThis study is testing if a drug called nanocrystalline megestrol acetate can help people with advanced lung cancer keep their appetite and body weight up while they undergo combined chemotherapy and radiation. It compares the drug to a placebo (inactive pill) when both are given …
Phase: PHASE3 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Mar 31, 2026 12:11 UTC
-
First test of new autoimmune drug in healthy volunteers
Knowledge-focused Recruiting nowThis is the first human study of an experimental drug called GenSci136, which is being developed for autoimmune diseases. Researchers are testing it in 48 healthy adults to check if it's safe and to see how the body processes it. The study will measure drug levels in the blood an…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Apr 01, 2026 22:41 UTC
-
First human tests begin for new drug candidate
Knowledge-focused Recruiting nowThis is an early safety study to see how healthy adults tolerate a new drug called GS3-007a. Researchers will give different doses to small groups of volunteers to check for side effects and measure how the drug moves through the body. The goal is to gather basic safety informati…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:30 UTC